ea0070aep662 | Pituitary and Neuroendocrinology | ECE2020
Chiloiro Sabrina
, Giampietro Antonella
, Bianchi Antonio
, Mirra Federica
, Donfrancesco Federico
, Maya Fleseriu Cara
, Lauretti Liveraba
, Anile Carmelo
, Gessi Marco
, Rindi Guido
, Pontecorvi Alfredo
, Fleseriu Maria
, Giustina Andrea
, De Marinis Laura
Background: Pegvisomant(PegV) and Pasireotide LAR(Pasi) are commonly used in acromegaly patients resistant to first-generation SRLs. Predictors of response to therapy with PegV and Pasi in this subset of patients are still unclear. These findings may be useful in choosing the most appropriate therapeutic option for the personalized treatment of patients affected by more aggressive disease. We aimed to identify individual predictors of responses.Methods: ...